Cargando…

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parkins, C S, Holder, A L, Hill, S A, Chaplin, D J, Tozer, G M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363526/ https://www.ncbi.nlm.nih.gov/pubmed/10952787 http://dx.doi.org/10.1054/bjoc.2000.1361

Ejemplares similares

Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy
por: Cemazar, M, et al.
Publicado: (2001)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy
por: Korbelik, M, et al.
Publicado: (2000)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
por: Dachs, Gabi U, et al.
Publicado: (2006)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts
por: Konerding, M A, et al.
Publicado: (1999)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
por: Beauregard, D. A., et al.
Publicado: (1998)

Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats
por: Nagashima, Yoshiyasu, et al.
Publicado: (2023)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019)

Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer
por: Eroğlu, A, et al.
Publicado: (1999)

Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice
por: Tang, Zhengshan, et al.
Publicado: (2020)

Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway
por: Stevens, Kathryn K, et al.
Publicado: (2017)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
por: Bao, Xin, et al.
Publicado: (2021)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model
por: Gao, Meng, et al.
Publicado: (2016)

Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats
por: Tochinai, Ryota, et al.
Publicado: (2018)

Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity
por: Ibrahim, Tarek S., et al.
Publicado: (2020)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma
por: Soini, Y, et al.
Publicado: (2000)

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions
por: de Wilt, J H W, et al.
Publicado: (2000)

Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography
por: Mampaey, Gitte, et al.
Publicado: (2022)

Morphologies, dimensions and targets of gastric nitric oxide synthase neurons
por: Di Natale, Madeleine R., et al.
Publicado: (2022)

Cortical Actin Nanodynamics Determines Nitric Oxide Release in Vascular Endothelium
por: Fels, Johannes, et al.
Publicado: (2012)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
por: Zhao, Bonan, et al.
Publicado: (2021)

Vascular nitric oxide: formation and function
por: Jin, Richard C, et al.
Publicado: (2010)

Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase
por: Berge, D L Van den, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_bsdvsucoapoi0i1p9amftlehvf